

Profiling Gene Expression Pattern Changes in HIV-1-Associated Kidney Disease


Keleabetswe Lerato Mpye

A thesis submitted to the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, in fulfilment of the requirements for the degree of Doctor of Philosophy.

Johannesburg, 2015

Declaration

I, Keleabetswe Lerato Mpye, hereby declare that this thesis is my own work. It is being submitted for the degree of Doctor of Philosophy in the University of the Witwatersrand, Johannesburg. It has not been submitted for any other degree or examination at any other University.

A handwritten signature in black ink, appearing to read 'Keleabetswe', is written over a horizontal line.

Keleabetswe Lerato Mpye

This 17th ____ day of June____, 2015.

Abstract

HIV-1 infected individuals are at risk of developing clinically and morphologically diverse renal complications. Most of the ensuing renal complications are similar to those observed in non-HIV patients while some are limited to HIV-infected patients. Kidney diseases are amongst the top 10 leading causes of death in the general population and affect over 10 % of the adult population. Two to ten percent of HIV-1 infected patients ultimately suffer chronic kidney disease, and specifically HIV-associated nephropathy (HIVAN), characterized clinically by nephrotic range proteinuria and histologically by collapsing focal segmental glomerulosclerosis (FSGS). Genetic mutations and disruption of the podocyte foot process and actin-based cytoskeleton architecture through dysregulation of its principal element, actin, or its associated proteins, lead to proteinuria and nephrotic syndrome. The majority of these proteins are susceptible to proteolysis by a lysosomal cysteine protease, cathepsin-L. The current study set out to profile changes in gene expression in HIVAN relative to HIV negative FSGS, minimal change disease (MCD) and non-proteinuric healthy controls. Probing the presence and localization of cathepsin-L and dynamin in these proteinuric kidney diseases, we showed that cathepsin-L and dynamin expression is enhanced in HIVAN and FSGS, relative to the healthy controls and MCD. We further profiled the expression of the 3 isoforms of cathepsin-L and dynamin using Quantitative reverse transcriptase PCR. *CTSL-3* expression was similar between all disease groups whilst *CSTL-2* was reduced relative to the normal tissue. There was most variation in the expression of *CSTL-1* between the disease tissues with down-regulation of *CSTL-1* in both HIVAN and FSGS relative to the control and MCD tissue. The expression of dynamin remained largely unchanged between the disease groups with the exception of *DYN-1* which was downregulated in MCD relative to FSGS. Given that dynamin expression was barely altered across the proteinuric states, compared to the healthy non-proteinuric controls, signifies that proteolysis of the actin-associated proteins synaptopodin and/or slit diaphragm-associated CD2AP by the cathepsins-L 2 and 3 was responsible for the proteinuria in HIVAN, FSGS and MCD. Our results show that FSGS manifests through attenuated CD2AP, up-regulated TGF- β 1 and cathepsin-L activity and not via dynamin degradation. The attenuated mRNA expression levels of dynamin, CD2AP and synaptopodin in renal tissue of the proteinuric kidneys validate that podocyte injury, in the form of loss of foot process integrity and slit diaphragm permeability, manifests through the over-expressed cathepsin-L enzymatic activity. Many of the genes that were altered in proteinuric kidney diseases, as observed from the pathway analysis of the PCR array data, are

mediated by transcriptional activation of nuclear factor kappa B (NF- κ B). Transcriptional mRNA expression levels, validated in real-time quantitative RT-PCR analysis illustrated that HIV-1 infection induces uncontrolled activation and induction of immunity and inflammatory responses, indicated by down-regulation of *SIGIRR*, and modulation of expression patterns of immunity and inflammatory response genes in proteinuric kidney diseases. Other genes that were down-regulated in HIVAN are involved in the MAPK JNK cellular signaling pathway and apoptosis. HIV-1 infection modulates expression patterns of the genes that are involved in immunity and inflammatory responses in proteinuric kidney disease, compromising the structure and function not only of the kidney but of the entire immune system.

This work is dedicated to:

The world's most beautiful and charismatic daughter, Agonnejaalo Mamotlopi, and my family who continuously support and encourage me in all I do.

My grandfather, Abram Ramotlopi Mphye (1928 – 2002), for always believing in me and sowing the seed of success in my life. You must be beaming with pride as you look down on us from the heaven above.

“Ke setlogolo sa Matebele, kgodumo e e lorole, Mohwaduba, Kgomo.

Pula!!!”

Acknowledgements

- i. My supervisors Dr. Raquel Duarte and Prof. Saraladevi Naicker for their guidance, for taking under their wing and giving me another chance at this degree
- ii. Thérèse Dix-Peek for always willing to help, discuss and resolve whatever the challenges I encountered. For the immense help with the statistical analysis of the data (even bringing in her personal computer for me to use), primer design and real-time PCR technique. For always having her office open for me to come vent, beg, the small talks and the good laughs
- iii. Dr Caroline Dickens for helping with the primer design
- iv. Dr Gago Saleshando for helping with the FFPE slides used for immunohistochemistry
- v. Alex Kasembeli for helping with FFPE tissue acquisition
- vi. Prof. Martin Hale, Dr. Pulane Mosiane and the staff at the Anatomical Pathology Department, National Health Laboratory Services, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, Johannesburg, for providing the FFPE tissue
- vii. Staff at the Anatomy Department, University of the Witwatersrand, Johannesburg, for allowing me to use their microscope
- viii. Dr Tanya Augustine for the CellProfiler course
- ix. Peter at the x-ray unit, area 623, Charlotte Maxeke Johannesburg Academic Hospital for making the developing station available to us at all times
- x. Kiashanee Moodley for sharing the strain of printing, collating the thesis and submission, and for always being enthusiastic to lend a helping hand
- xi. Members of the “Nephroncology” Research Unit, University of the Witwatersrand, Johannesburg, for the support and being a family to me
- xii. The National Research Foundation, Poliomyelitis Research Foundation, the NKFSAdcock Ingram and David Hepburn Awards for funding
- xiii. Mama for the financial and emotional support throughout my studies
- xiv. My cousin Kefilwe Balulu for giving up her precious time to take care of 2 months old daughter so that I can go back to the lab to complete this degree
- xv. Mmane Anna for being a mother and a best friend every step of the way. You are remarkably splendid

- xvi. My family: Sonia, Thapelo, Itu, Ago and daddy for their unwavering support and keeping me going
- xvii. Kgothatso Ramaeto, Jabu Maleka and Kwena Nkoana for volunteering their laptops when mine bailed-out on me at the 11th hour. I am blessed
- xviii. My friends and everyone else for their contributions
- xix. I profusely thank the Lord for His grace, abundant blessings and for giving me a purpose in life. I am highly favoured and eternally grateful

Research outputs

Keleabetswe Lerato Mpye, Therésè Dix-Peek, Caroline Dickens, Jaya George, Saraladevi Naicker and Raquel Duarte. *HIV-1-Associated Kidney Disease: Disease- and Signaling Pathway-Specific Gene Expression Alterations*. World Congress of Nephrology (WCN), March 2015. Cape Town, South Africa. Poster presentation

Keleabetswe Lerato Mpye, Thérèse Dix-Peek, Jaya George, Gago Saleshando, Mpoti Seboka, Saraladevi Naicker and Raquel Duarte. *Profiling Gene Expression Pattern Changes in HIV-1-Associated Kidney Disease*. University of the Witwatersrand Health Sciences Research day, September 2014. Johannesburg, South Africa. Oral presentation

Keleabetswe Lerato Mpye, Thérèse Dix-Peek, Jaya George, Gago Saleshando, Mpoti Seboka, Saraladevi Naicker and Raquel Duarte. *Profiling Gene Expression Pattern Changes in HIV-1-Associated Kidney Disease*. South African Society of Biochemistry and Molecular Biology (SASBMB), July 2014, Cape Winelands, South Africa. Poster presentation

Table of contents

Declaration	ii
Abstract	iii
Dedications	v
Acknowledgements	vi
Research outputs	viii
Table of contents	ix
List of figures	xiii
List of tables	xv
ist of abbreviations	xvii
1. BACKGROUND	1
1.1. Kidneys: An overview	1
1.2. Kidney diseases	6
1.2.1. Chronic kidney disease	8
1.2.2. Focal segmental glomerulosclerosis	8
1.2.3. HIVAN and HIVICK	9
1.3. Human immunodeficiency virus	11
1.4. HIV-1 acquisition in renal cells	13
1.5. HIV-1 genes implicated in HIVAN manifestation	14
1.6. Host genes and gene products implicated in renal disease	15
1.6.1. Dynamin	16
1.6.2. Cathepsin-L	17
1.6.3. Synaptopodin	18
1.6.4. CD2-associated protein	19
1.6.5. NPHS1 and NPHS2	20

1.7.	HIV renal disease and treatment	21
1.8.	Antiretroviral drug-induced nephrotoxicity	21
	Study hypothesis	24
	Aim	24
	Objectives	24
2.	MATERIALS AND METHODS	25
2.1.	Sample acquisition	25
2.2.	Immunohistochemistry	25
2.3.	RNA isolation, purification and quantification.....	28
2.4.	Template preparation	29
2.5.	Primer design	32
2.6.	Real-time quantitative polymerase chain reaction for assessing cathepsin-L and dynamin expression	32
2.7.	Determining expression levels of podocyte cytoskeleton proteins.....	39
2.8.	PCR arrays	39
2.9.	Validation of PCR arrays	44
2.9.1.	Validation of altered HIV-host response genes.....	44
2.9.2.	Validation of altered TLR genes	47
2.10.	Protein extraction.....	49
2.11.	Western-blotting	49
2.12.	Data analysis	51
2.12.1.	Immunohistochemistry quantification	51
2.12.2.	Statistical analysis of qPCR data	51
3.	RESULTS	52
3.1.	Immune-markers, cathepsin-L and dynamin, localization.....	52

3.2.	Cathepsin-L and dynamin expression patterns	62
3.2.1.	Transcriptional mRNA expression of cathepsin-L and dynamin	62
3.2.2.	Western-blot validation of cathepsin-L and dynamin protein expression.....	65
3.3.	Expression patterns of podocyte cytoskeleton proteins	69
3.4.	Polymerase chain reaction arrays.....	72
3.4.1.	HIV host response PCR arrays	73
3.4.1.1.	qPCR validation of altered HIV-host response genes	76
3.4.2.	Toll-like receptor PCR arrays.....	81
3.4.2.1.	Western-blot validation of altered TLR proteins	81
3.4.2.2.	qPCR validation of altered TLR genes	86
4.	DISCUSSION	89
	Dynamin localization in the kidney	89
	Cathepsin-L localization in the kidney	90
	Cathepsin-L and dynamin expression levels in renal tissue	91
	Cathepsin-L enzymatic activity in the podocyte cytoskeleton	92
	Altered host genes and pathways.....	93
	Concluding remarks	98
	Study limitations and future work.....	100
5.	REFERENCES	101
	Appendix.....	121
	Ethics clearance certificate	121
	Copyright certification	122
	Immunohistochemistry	127
	RNA isolation, purification and quantification.....	127
	Template preparation	128

PCR arrays	129
Sodium dodecyl sulphate polyacrylamide gel electrophoresis	137
Western-blotting	138

List of figures

Figure 1: Kidney cross-section	2
Figure 2: Glomerular filtration barrier	3
Figure 3: Schematic representation of actin-based podocyte cytoskeleton	5
Figure 4: Re-organization of the Podocyte cytoskeleton and proteinuria.....	7
Figure 5: Genomic organization of HIV-1.....	12
Figure 6: HIV-1 life-cycle	23
Figure 7: A representative of a light microscopy section of negative control kidney tissue	53
Figure 8: Probing cathepsin-L and dynamin expression and localization in renal tissue.....	55
Figure 9: Comprehensive analysis of cathepsin-L and dynamin distribution within the kidney..	56
Figure 10: CellProfiler analyzed images.....	57
Figure 11: Quantification of immunohistochemical marker localization	58
Figure 12: qPCR renal cathepsin-L expression	64
Figure 13: Box-Whisker plots of qPCR renal dynamin expression.....	67
Figure 14: Western-blot analysis of cathepsin-L and dynamin expression	68
Figure 15: Expression patterns of podocyte cytoskeleton proteins	70
Figure 16: HIV Host Response Panel arrays gene expression pattern in HIVAN vs HIV negative FSGS	74
Figure 17: HIV Host Response Panel arrays gene expression pattern in HIVAN and HIV negative FSGS compared to the healthy non-proteinuric controls	75
Figure 18: mRNA expression patterns of altered <i>CCL4</i> , <i>CXCL12</i> and <i>SLPI</i> from HIV-1 host response panel of arrays.....	77
Figure 19: Altered HIV-host response genes in HIVAN and the HIV negative FSGS relative to healthy controls	79
Figure 20: Toll-Like Receptor arrays gene expression pattern of HIVAN vs HIV negative FSGS	82
Figure 21: Toll-Like Receptor arrays gene expression pattern in HIVAN and HIV negative FSGS compared to the healthy non-proteinuric controls	83
Figure 22: MAPK signaling pathway	84
Figure 23: Western-blot analysis of JNK proteins.....	85

Figure 24: mRNA expression of altered TLR array genes in HIVAN and HIV negative FSGS relative to the healthy control.	87
Figure 25: Gene expression pattern changes in HIV-1-associated kidney disease.....	99

List of tables

Table 1: Preparation of the High Capacity cDNA 2 × reverse transcription master mix	30
Table 2: Thermo-cycling conditions for cDNA synthesis using High Capacity cDNA reverse transcription kit	31
Table 3: Primer sequences of cathepsin-L and dynamin genes	33
Table 4: Primer sequences of reference genes	34
Table 5: Preparation of real time quantitative PCR reaction mix using Brilliant II SYBR.....	35
Table 6: Thermo-cycling conditions for real time quantitative PCR reaction using Brilliant II SYBR.....	37
Table 7: Primer sequences used for actin-associated cytoskeleton gene products.	40
Table 8: Real-time PCR cycling conditions for pre-amplification of cDNA target template used in RT ² PCR array experiments.....	42
Table 9: Real-time cycling conditions used for RT ² PCR array experiments	43
Table 10: Primer sequences for up- or down-regulated HIV-host response genes in HIVAN compared to HIV negative FSGS	45
Table 11: Primer sequences for altered HIV-host response genes in HIVAN and HIV negative FSGS compared to the healthy controls.....	46
Table 12: Primers for altered TLR genes in FSGS and HIVAN compared to healthy controls...	48
Table 13: Comparison of glomerular cathepsin-L and dynamin localization intensities between disease states	59
Table 14: Comparison of tubular cathepsin-L and dynamin localization intensities between disease states	60
Table 15: Comparison of qPCR expression levels of cathepsin-L in the kidneys of proteinuric groups and the healthy non-proteinuric controls.	63
Table 16: Comparison of qPCR expression levels of dynamin in the kidneys of proteinuric groups and the healthy non-proteinuric controls.	66
Table 17: Comparison of qPCR expression patterns of actin-associated podocyte cytoskeleton gene products in proteinuric kidney diseases and the healthy controls.	71
Table 18: Comparison of qPCR expression patterns of CCL4, CXCL12 and SLPI genes in proteinuric kidney diseases and the healthy controls.....	78

Table 19: Comparison of qPCR expression patterns of HIV-host response genes in proteinuric kidney diseases compared to healthy controls.	80
Table 20: Comparison of qPCR expression patterns of <i>CCL2</i> and <i>REL1</i> genes was assessed. ...	88

List of abbreviations

°C	Degrees Celsius
ΔG	Change in Gibbs free energy
$2^{-\Delta\Delta C_q}$	Fold change
AIDS	Acquired immune deficiency syndrome
APS	Ammonium persulfate
ARV	Antiretroviral
C_t	Cycle threshold
C_q	Quantification cycle
<i>CCL2</i>	Chemokine (C-C Motif) ligand 2 or Monocyte chemoattractant protein 1
<i>CCL3</i>	Chemokine (C-C Motif) ligand 3 or Macrophage inflammatory protein 1- α
<i>CCL4</i>	Chemokine (C-C Motif) ligand 4
CCR5	Chemokine (C-C motif) receptor 5
<i>CDKN1A</i>	Cyclin-dependent kinase inhibitor 1A
CKD	Chronic kidney disease
<i>CXCL12</i>	Chemokine (C-X-C Motif) Ligand 12
CXCR4	Chemokine (C-X-C motif) receptor 4
Da	Daltons
DMEM	Dulbeco's modified eagle medium
DMSO	Dimethylsulphoxide
DTT	Dithiothreitol
DNA	Deoxyribonucleic acid
EDTA	Ethylenediaminetetraacetic acid
Env	Envelope glycoprotein
ERK	Extracellular signal-regulated kinase
ESL	Endothelial surface layer
ESRD	End-stage renal disease
FSGS	Focal segmental glomerulosclerosis
GBM	Glomerular basement membrane
H ₂ O	Water

H ₂ O ₂	Hydrogen peroxide
HAART	Highly active antiretroviral treatment
HCl	Hydrochloric acid
HIV-1	Human immunodeficiency virus type I
HIVAN	Human immunodeficiency virus-associated nephropathy
HIVICK	Human immunodeficiency virus immune complex kidney disease
<i>HMGB1</i>	High Mobility Group Box 1
IFN- γ	Interferon gamma
IHC	Immunohistochemistry
IL-1 β	Interleukin-1 beta
IRAK	Interleukin-1 receptor-associated kinases
JNK	c-Jun NH2-terminal kinase
ℓ	Litre
LY96	Lymphocyte antigen 96
M	Molar
MAPK	Mitogen-Activated Protein Kinases
<i>MAP3K1</i>	Mitogen-Activated Protein Kinase Kinase Kinase 1
<i>MAP4K4</i>	Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4
<i>MAPK8</i>	Mitogen-Activated Protein Kinase 8
$\mu\ell$	Microlitre
m ℓ	Millilitre
NaCl	Sodium chloride
<i>NPHS1</i>	Nephrosis 1, congenital, Finnish type (nephrin)
<i>NPHS2</i>	Nephrosis 2, idiopathic, steroid-resistant (podocin)
NRTI	Nucleoside reverse transcriptase inhibitor
PAGE	Polyacrylamide gel electrophoresis
PBS	Phosphate buffered saline
PCR	Polymerase chain reaction
<i>PELI1</i>	Pellino E3 Ubiquitin Protein Ligase 1
PI	Protease inhibitor
qPCR	Quantitative polymerase chain reaction

RAG	Recombination activating gene
REL	V-rel reticuloendotheliosis viral oncogene homolog (avian)
RNA	Ribonucleic acid
RPL13A	<i>Homo sapiens</i> ribosomal protein L13a
rpm	Revolutions per minute
RT	Reverse transcriptase
SDHA	<i>Homo sapiens</i> succinate dehydrogenase complex, subunit A, flavoprotein
SDS	Sodium dodecyl sulphate
SERPINA1	Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin)
SIGIRR	Single Immunoglobulin and Toll-Interleukin 1 Receptor (TIR) Domain
SLPI	Secretory Leukocyte Peptidase Inhibitor
STAT1	Signal transducer and activator of transcription 1
SYNPO	Synaptopodin
TEMED	N, N, N', N'-Tetramethylethylenediamine
TGF- β 1	Transforming growth factors beta 1
TLR	Toll-like receptor
TNF α	Tumor necrosis factor alpha
TNFSF10	Tumor necrosis factor (ligand) superfamily , member 10
TRAF6	Tumor necrosis factor receptor associated factor
μ l	Micro litre
VDJ	Variable, diversity and joining
x g	Times gravity (relative centrifugal force)
YWHAZ	<i>Homo sapiens</i> tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide.

The IUPAC-IUBMB one and three letter notations for the amino acids have been used.